Pfizer launches human trials for coronavirus vaccine, aims for emergency use in September
Pfizer, in partnership with German pharmaceutical company BioNTech, became the latest company to launch human trials for a potential coronavirus vaccine Monday.
If all goes well, the companies hope their COVID-19 vaccine could be ready for emergency use in September, in time for what many predict will be a period of rejuvenated viral transmission (if it subsides at all in the U.S. between now and then). The normal caveats apply here — the quest for a vaccine is moving along at a pace never before seen, which means that some essential steps may be purposefully skipped in the process, and many experts believe that getting a vaccine in even 18 months, let alone later this year, is overly optimistic.
Pfizer and some other companies are using a genetic material known as messenger RNA to develop their vaccine that could possibly train cells to create a protein the coronavirus latches onto without making a person sick. With the protein in the body, a person's immune system could then reportedly produce antibodies ready to fight off a future infection. The good news is that this technology is reportedly more stable than traditional vaccines which use weakened virus strains, and it's faster to produce, hence Pfizer's ambitious timeline. The catch is that no RNA messenger vaccine has ever reached the market before.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
In other coronavirus development news, the United Arab Emirates found that a "minimally invasive" treatment in which stem cells are turned into a mist to be inhaled has resulted in "favorable" outcomes for COVID-19 patients and could hit the market in three months if trials keep going well. Israel, meanwhile, said it has isolated a key coronavirus antibody that could possibly "neutralize" the virus in a patient's body.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Unpasteurised milk and the American right
Under the radar Former darling of health-conscious liberal foodies is now a 'conservative culture war signal': a sign of mistrust in experts
By Harriet Marsden, The Week UK Published
-
Government shutdown looming? Blame the border
Talking Points Democrats and Republicans say funding for immigration enforcement is the budget battle's latest sticking point. That's about all they agree on.
By Rafi Schwartz, The Week US Published
-
'Conservatives have not limited their attack on reproductive rights to the US'
Instant Opinion Opinion, comment and editorials of the day
By Harold Maass, The Week US Published
-
Seattle Children's Hospital sues Texas over 'sham' demand for transgender medical records
Speed Read Texas Attorney General Ken Paxton subpoenaed records of any Texan who received gender-affirming care at the Washington hospital
By Peter Weber, The Week US Published
-
Afghanistan has a growing female suicide problem
Speed Read The Taliban has steadily whittled away women's and girls' rights in Afghanistan over the past 2 years, prompting a surge in depression and suicide
By Peter Weber, The Week US Published
-
US life expectancy rose in 2022 but not to pre-pandemic levels
Speed Read Life expectancy is slowly crawling back up
By Devika Rao, The Week US Published
-
Vallance diaries: Boris Johnson 'bamboozled' by Covid science
Speed Read Then PM struggled to get his head around key terms and stats, chief scientific advisor claims
By The Week UK Published
-
An increasing number of dog owners are 'vaccine hesitant' about rabies
Speed Read A new survey points to canine vaccine hesitancy
By Devika Rao, The Week US Published
-
Anger may be a powerful motivator for tough goals, new study suggests
Speed Read Keeping your cool might actually be less efficient than letting your anger drive you
By Theara Coleman, The Week US Published
-
A tropical skin disease is making the rounds in the US
Speed Read Leishmaniasis is endemic to the country and can cause ulcers and disfiguration
By Devika Rao, The Week US Published
-
FDA moves to ban menthol cigarettes
Speed Read It's been a long time coming
By Devika Rao, The Week US Published